The treatment of hypertension in obese patients

Current Hypertension Reports

Volumn 10, Issue 2, 2008, Pages 143-150

  Wofford, Marion R ^a   Smith, Grant ^b   Minor, Deborah S ^b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMFEBUTAMONE; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; FELODIPINE; FLUOXETINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; METOPROLOL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; RIMONABANT; SERTRALINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TOPIRAMATE; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL; ZONISAMIDE; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT;

BARIATRIC SURGERY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CALORIC RESTRICTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CORRELATION ANALYSIS; DIET THERAPY; DISEASE ASSOCIATION; DROWSINESS; EPIDEMIOLOGICAL DATA; ETHNIC DIFFERENCE; EXERCISE; FRUIT; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LOW FAT DIET; MEDICAL DECISION MAKING; MONOTHERAPY; NEUROLOGIC DISEASE; OBESITY; POSITIVE END EXPIRATORY PRESSURE; PREVALENCE; QUALITY OF LIFE; RACE DIFFERENCE; REVIEW; SEDATION; SIDE EFFECT; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; VEGETABLE; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; AGE; BLOOD PRESSURE; LIFESTYLE; MOTOR ACTIVITY; RISK FACTOR;

AGE FACTORS; ANTI-OBESITY AGENTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; EXERCISE; HUMANS; HYPERTENSION; LIFE STYLE; MOTOR ACTIVITY; OBESITY; PREVALENCE; RISK FACTORS; WEIGHT GAIN; WEIGHT LOSS;

EID: 52049116541     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0027-9     Document Type: Review

References (50)

1. Ezzati M, Lopez AD, Rodgers A, et al.: Selected major risk factors and global and regional burden of disease. Lancet 2002, 360:1347-1360.
2. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
3. Ong KL, Cheung BM, Man YB, et al.: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49:69-75.
4. National Institutes of Health, National Heart, Lung, and Blood Institutes: Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998, 6(Suppl 2):51S-209S.
5. Poirier P, Giles TD, Bray GA, et al.: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 2006, 113:898-918.
6. Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
7. Kannel WB, Brand N, Skinner JJ, et al.: The relation of adiposity to blood pressure and development of hypertension: the Framingham Study. Ann Intern Med 1967, 67:48-59.
8. Garrison RJ, Kannel WB, Stokes JS, et al.: Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987, 16:235-251.
9. Dyer AR, Elliott P: The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Cooperative Research Group. J Hum Hypertens 1989, 3:299-308.
10. Hall JE: The kidney, hypertension, and obesity. Hypertension 2003, 41:625-633.
11. Esler M, Straznicky N, Eikelis N, et al.: Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006, 48:787-796.
12. Alvarez GE, Beske SD, Ballard TP, Davy KP: Sympathetic neural activation in visceral obesity. Circulation 2002, 106:2533-2536.
13. Shibao C, Gamboa A, Diedrich A, et al.: Autonomic contribution to blood pressure and metabolism in obesity. Hypertension 2007, 49:27-33.
14. Kassab S, Kato T, Wilkins D, et al.: Renal denervation attenuated the sodium retention and hypertension associated with obesity. Hypertension 1995, 25:893-897.
15. Wofford MR, Hall JE: Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004, 10:3621-3637.
16. Rahmouni K, Correia MLG, Haynes WG, Mark AL: Obesity-associated hypertension: new insights into mechanisms. Hypertension 2004, 45:9-14.
17. Engeli S, Böhnke J, Gorzelniak K, et al.: Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005, 45:356-362.
18. Massiéra F, Bloch-faure M, Ceiler D, et al.: Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001, 15:2727-2730.
19. Boustany CM, Bharadway K, Daugherty A, et al.: Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. Am J Physiol 2004, 287:R943-R949.
20. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, et al.: Human adipocytes secrete mineralocorticoid releasing factors. Proc Natl Acad Sci U S A 2003, 100:14211-14216.
21. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM: Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004, 125:112-117.
22. de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004, 43:41-47.
23. Rahmouni K, Morgan DA, Morgan GM, et al.: Role of selective leptin resistance in diet-induced obesity hypertension. Diabetes 2005, 54:2012-2018.
24. Lichetenstein AL, Appel LJ, Brands M, et al.: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006, 114:82-96.
25. Whelton P, Appel LJ, Espeland MA, et al.: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1989, 279:839-846.
26. The Trials of Hypertension Prevention Collaborative Research Group: The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. JAMA 1992, 267:1213-1220.
27. He J, Whelton PD, Appel LJ, et al.: Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000, 35:544-549.
28. Appel LJ, Brands MW, Daniels SR, et al.: Dietary approaches to prevent and treat hypertension: a scientific statement for the American Heart Association. Hypertension 2006, 47:296-308.
29. Lopes HF, Martin KL, Nashar K, et al.: DASH diet lowers blood pressure and lipid induced oxidative stress in obesity. Hypertension 2003, 41:422-430.
30. Blair SM, Goodyear NN, Gibbons LW, Copper KH: Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 1984, 52:487-490.
31. Paffenbarger RS Jr, Hyde RT, Wing AL, et al.: The association of changes in physical- activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993, 328:538-545.
32. Whelton SP, Chin A, Xin X, et al.: Effect of aerobic exercise on blood pressure; a metaanalysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
33. Wolk R, Shamsuzzaman AS, Somers VK: Obesity, sleep apnea, and hypertension. Hypertension 2003, 42:1067-1074.
34. Weiss JW, Remsburg S, Garpestad E, et al.: Hemodynamic consequences of obstructive sleep apnea: state of the art review. Sleep 1996, 19:388-397.
35. Nieto FJ, Young TB, Lind BK, et al.: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study: Sleep Heart Health Study. JAMA 2000, 283:1829-1836.
36. Reisin E, Weir MR, Falkner B, et al.: for the Treatment in Obese Patients with Hypertension (TROPHY) Study Group: Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Hypertension 1997, 30:140-145.
37. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial. JAMA 2002, 288:2981-2997.
38. Gress TW, Neito FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
39. Julius S, Kjeldsen SE, Weber M, et al.: for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031.
40. Lindholm LH, Ibsen H, Borch-Johnsen K, et al.: Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002, 20:1879-1886.
41. Jordan J, Engeli S, Boye SW, et al.: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007, 49:1047-1055.
42. Dahlöf B, Sever PS, Poulter NR, et al.: for the ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
43. Wofford MR, Anderson DC, Brown CA, et al.: Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects. Am J Hypertens 2001, 14:164-168.
44. Fogari R, Derosa G, Zoppi A, et al.: Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005, 28:209-214.
45. Masuo K, Mikami H, Ogihara T, Tuck ML: Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens 2001, 14:530-538.
46. Snow V, Barry P, Fitterman N, et al.: for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians: Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005, 142:525-541.
47. Derosa G, Cicero AF, Murdolo G, et al.: Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005, 7:47-55.
48. Scholze J, Grimm E, Herrmann D, et al.: Optimal treatment of obesity-related hypertension: the hypertension-obesity-sibutramine (HOS) study. Circulation 2007, 115:1991-1998.
49. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: for the RIO-North America Study Group: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardio-metabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
50. Scheen AJ, Finer N, Hollander P, et al.: for the RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1670.